ADT with EBRT and Brachytherapy

Posted by hanscasteels @hanscasteels, Dec 5 8:44am

Apologies for perhaps asking a redundant question. There are some recent studies that claim that a dose of ADT, when selecting EBRT and a Brachytherapy boost as a therapy method, really doesn’t result in mortality rates (or perhaps, survival rate) differential. I am aware that, just like in any business, changing what has become mantra, is immensely difficult. Given the nefast effecten of testosteron depreciation, is there any further insight on the usefulness or effectiveness of the various pharmaceuticals as a treatment component for prostate cancer (with cribriform)

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

jeffmarc | @jeffmarc | Dec 5 10:16am

ADT has been shown to reduce the size of metastasis making it easier to completely remove them and prevent them from growing any further. I suspect this could make a difference in some of the cases. What study did you see showing that it had no beneficial affects at all to go on ADT Before treatment?

hanscasteels | @hanscasteels | Dec 5 10:57am

It's a YouTube video called "the royal flush" .I unfortunately cannot post the link

jeffmarc | @jeffmarc | Dec 5 11:13am

In reply to @hanscasteels "It's a YouTube video called "the royal flush" .I unfortunately cannot post the link" + (show)

I found the Video. It was related to brachytherapy and ADT use not being beneficial, it didn’t seem to include other treatments like SBRT or surgery not benefiting from ADT.

Definitely made a case for using more brachytherapy In the US, where the usage has declined.

callibaetis | @callibaetis | Dec 5 1:07pm

Here's a link from the recent ASTRO meeting regarding the addition of EBRT to brachytherapy.
https://www.medscape.com/viewarticle/adding-ebrt-brachytherapy-did-not-improve-higher-risk-2024a1000hzs
The impression that I got from the Royal Flush presentation by Mira Keyes was that the combination therapy was beneficial in high risk patients in that it shortened the length of time on ADT. But, showed no improvement in overall survival.

The link to her presentation is:

All of this begs the question as to how to approach unfavorable intermediate and high risk patients especially when considering higher Gleason scores, high Decipher scores, etc.

Sure, they come out with this stuff after I've completed brachytherapy, IMRT and am on the last legs of ADT!